Blog

MCLEAN, VA / ACCESS Newswire / October 1, 2025 / Gladstone Commercial Corporation (Nasdaq:GOOD) (“Gladstone Commercial”) is pleased to announce the acquisition of an industrial portfolio totaling 693,236 square feet of manufacturing, distribution, and warehouse space across six locations in Michigan, Indiana, and Georgia. Concurrent with the $54.5 million acquisition, Gladstone Commercial leased back the facilities via a 20-year absolute net lease to TI Group Automotive Systems, L.L.C. and its affiliate (“TI Automotive”), a global tier 1 automotive supplier.

“The acquisition of this portfolio continues our efforts to add manufacturing and industrial facilities leased to credit-worthy tenants to our real estate portfolio,” stated Ryan Carter, Executive Vice President of Gladstone Commercial.

“We are pleased to have executed a cross-regional portfolio, reflecting our disciplined approach to sourcing and closing complex sale-leaseback transactions. These facilities are essential to TI Automotive’s business and serve as key manufacturing and distribution hubs,” said Todd McDonald, Senior Vice President of Gladstone Commercial.

“This acquisition advances our strategy of building a durable industrial portfolio in key U.S. manufacturing markets. The portfolio is secured by a long-term absolute net lease in markets that continue to benefit from strong manufacturing demand. The transaction extends our weighted average lease term and enhances the overall quality and stability of our portfolio,” said Buzz Cooper, President of Gladstone Commercial.

About Gladstone Commercial (Nasdaq:GOOD)

Gladstone Commercial is a real estate investment trust focused on acquiring, owning and operating net leased industrial and office properties across the United States. As of June 30, 2025, Gladstone Commercial’s real estate portfolio consisted of 143 properties located in 27 states, totaling approximately 17.0 million square feet. For additional information, please visit www.gladstonecommercial.com.

For Broker Submittals:

Midwest/West		South Central
Ryan Carter		Todd Alan McDonald
Executive Vice President		Senior Vice President
(571) 451-0019		(703) 287-5895
Ryan.Carter@gladstone.com		Todd.McDonald@gladstone.com
Southeast/Northeast
Nick Lindsay
Vice President
(703) 966-3864 Nick.Lindsay@gladstone.com

Investor or Media Inquiries:

Buzz Cooper		Catherine Gerkis
President		Director of Investor Relations/ESG
(703) 287-5815		(703) 287-5846
Buzz.Cooper@gladstone.com		Catherine.Gerkis@gladstone.com

All statements contained in this press release, other than historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements involve inherent risks and uncertainties as they relate to expectations, beliefs, projections, future plans and strategies, anticipated events, or trends concerning matters that are not historical facts and may ultimately prove to be incorrect or false. Forward-looking statements include information about possible or assumed future events, including, without limitation, those relating to the discussion and analysis of Gladstone Commercial’s business, financial condition, results of operations, and our strategic plans and objectives. Words such as “may,” “might,” “believe,” “will,” “anticipate,” “future,” “could,” “growth,” “plan,” “intend,” “expect,” “should,” “would,” “if,” “seek,” “possible,” “potential,” “likely” and variations of these words and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these words. Forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those included within or contemplated by such statements, including, but not limited to, the description of risks and uncertainties in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC on February 18, 2025, and certain other filings made with the SEC. Gladstone Commercial cautions readers not to place undue reliance on any such forward-looking statements which speak only as of the date made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

For further information: Gladstone Commercial Corporation, (703) 287-5893

For Investor Relations inquiries related to any of the monthly dividend paying Gladstone funds, please visit www.gladstonecompanies.com.

SOURCE: Gladstone Commercial Corporation

View the original press release on ACCESS Newswire

MCLEAN, VA / ACCESS Newswire / October 1, 2025 / Gladstone Alternative Income Fund (“Gladstone Alternative” or the “Fund”) announced today that its board of trustees declared monthly cash distributions to shareholders for the month of October. The October distribution amount is $0.00194 per calendar day for each issued and outstanding Class A share, Class C share, and Class I share for the period beginning October 1, 2025 and ending October 31, 2025 (for shareholders who own shares all 31 days in October, the distribution will total $0.06014 per share). The distributions will be paid on October 31, 2025 for Dividend Reinvestment Plan (“DRIP”) participants and November 3, 2025 for non-DRIP participants.

John Sateri, President of Gladstone Alternative, noted, “We are pleased to announce the eighth consecutive monthly dividend for Gladstone Alternative, continuing our commitment to delivering consistent income to our investors. We look forward to continuing to create long-term value in the months and years ahead by generating sustainable returns for our shareholders while providing them access to a diversified portfolio of private credit and equity investments.”

About Gladstone Alternative Income Fund

Gladstone Alternative Income Fund is a non-diversified, unlisted, closed-end management investment company registered under the Investment Company Act of 1940 and is operating as an interval fund. The Fund seeks to achieve and grow current income by investing primarily in directly originated loans to lower and middle market private businesses in the United States, broadly syndicated loans and commercial real estate loans.

Investors are advised to carefully consider the investment objectives, risks and charges, and expenses of Gladstone Alternative Income Fund before investing. The prospectus, dated July 29, 2025, which has been filed with the U.S. Securities and Exchange Commission, and as supplemented from time to time, contains this and other information about the Fund and should be read carefully before investing. You may get these documents for free by visiting the Fund’s website at www.gladstoneintervalfund.com or by visiting EDGAR on the SEC’s website at www.sec.gov. To obtain a copy of the prospectus, you may also contact Gladstone Securities, LLC, the dealer manager and distributor for this offering, which will arrange to send you the prospectus if you request it by calling toll-free at (833) 849-5993.

For further information, please visit our website at www.gladstoneintervalfund.com.

SOURCE: Gladstone Alternative Income Fund

View the original press release on ACCESS Newswire

Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage – NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections

SHELTON, CONNECTICUT / ACCESS Newswire / September 30, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2025 with the Securities and Exchange Commission (SEC) on Monday, September 29, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000110465925094527/nnvc-20250630x10k.htm).

In the fiscal year 2025, we have achieved a substantial level of accomplishments. We have focused on evaluating the broad spectrum of antiviral activity of NV- 387.

We believe that NV-387 is on its way to become a revolutionary antiviral therapy that could be prescribed for practically any respiratory viral infection without first testing for the causative virus, just as broad-spectrum antibiotics can be prescribed even before testing for the causative bacteria. This “emperic therapy” approach would enable immediate treatment and thus improve effectiveness; it is well known that antiviral treatments are most effective when given early.

NV-387 would play in a market size of well over $20 Billion as a dominant player, if approved for such emperic therapy of viral ARI/SARI.

To this end, we have proposed a novel adaptive, Phase II clinical trial for the evaluation of NV-387 as a treatment for Viral Acute/Severe Acute Respiratory Infections (V-ARI, V-SARI) towards this goal. A preliminary clinical protocol for this complex trial has been developed.

At present, we are fully engaged in completing the Clinical Trial Application (CTA) for a Phase II clinical trial of NV-387 for the treatment of MPox disease in Africa. MPox continues to spread and surge in African countries and is endemic in the Democratic Republic of Congo (DRC) and neighboring countries. Due to this, African CDC has continued its declaration of Public Health Emergency of Continental Security (PHECS), initiated in August 2024, as of September, 2025. We have already obtained a preliminary approval for our clinical trial protocol for this clinical trial from the regulatory agency in charge, namely ACOREP in DRC.

We plan on leveraging the MPox studies towards approval of NV-387 as a treatment of Smallpox under the US FDA “Animal Rule”. The US agency BARDA has programs to support such development if NV-387 qualifies.

A potential acquisition of NV-387 for Smallpox under the US Strategic National Stockpile (US-SNS) if approved could be worth of the order of $1 billion over five years. We believe (i) NV-387 for treatment of MPox, (ii) NV-387 for the treatment of Smallpox, and (iii) NV-387 for the treatment of Measles, would be separately eligible for Orphan Drug Designation (ODD) by the US FDA. An ODD carries several benefits. Certain FDA fees would be waived. Up to seven years of market exclusivity would become available. There are also research and development tax benefits. In addition, some of these programs may be eligible for issuance of a tradable “Priority Review Voucher” (PRV) upon drug approval. A PRV if issued to us would in itself be a revenue generator with a value of over $150 million.

Smallpox is a bioterrorism threat. Two drugs, namely, tecovirimat and brincidofovir were approved in the USA for Smallpox under the FDA “Animal Rule” and have been acquired in the US-SNS. Both of these drugs have limitations. Therefore, the US agency BARDA is searching for a new drug. We believe NV-387 matches their requirements.

MPox Clade II is endemic in the USA and some European countries. MPox Clade Ia and Ib are more severe strains than Clade IIa or IIb, and are spreading in Africa. Clade Ia/Ib strains could break out of Africa globally and thereby cause severe pandemics. MPox is a much less severe cousin of Smallpox when compared in terms of the pathogenic effects and case fatality rates of the virus.

There is no drug for treatment of MPox at present. Tecovirimat failed in clinical trials for the treatment of MPox ^[1], ^[2]. Brincidofovir entered clinical trials for MPox in January, 2025, and interim results were anticipated in Q1 2025, according to the press release by Africa CDC ^[3]. The current status of this brincidofovir for MPox clinical trial is not publicly known ^[4] . Brincidofovir carries a black box warning due to increased mortality rates in another indication, causes elevation of liver damage-related markers, is a carcinogen, may cause embryonic or fetal harm, and may irreversibly impair fertility, according to its prescribing information ^[5], limiting its applicability.

Thus we believe NV-387 has a wide opportunity as a treatment of MPox, which can be currently estimated to be a market size approaching $1 Billion in African region alone.

We reported that, as of June 30, 2025, we had cash and cash equivalent current assets balance of approximately $1.67 Million. In addition, we reported approximately $6.83 Million in Net Property and Equipment (P&E) assets (after depreciation). The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT, where we manufacture our clinical trial drug substance and drug products, thus producing substantial savings as compared to working with an external manufacturer (CDMO). The total current liabilities were approximately $1.31 Million. In comparison, as of June 30, 2024, we had cash and cash equivalent balance of approximately $4.97 Million, P&E assets of approximately $7.5 Million (after depreciation), and total current liabilities of approximately $1.36 Million.

The net cash utilized in the reported period for operating activities was approximately $8.48 million, which includes continuing expenditures for completion of the Phase Ia/Ib clinical trial of NV-387 in India, and R&D and preparatory work including cGMP manufacture of the drug substance for the Phase II clinical trial of NV-387 for treatment of MPox in Africa.

We raised approximately $5.3 million in net cash from financing activities, which comprised of an “At-the-Market” offering in an ATM Agreement with D. Boral Capital.

Subsequent to the reported period, we have raised approximately $1 million additional under the said ATM. Further, our founder, Dr. Anil Diwan has provided a line of credit (LOC) of $3 million to the Company. We have not yet drawn on the LOC. As such, we reported that we do not have sufficient funding in hand as of now to continue operations through September 30, 2026, for our planned objectives. As a result substantial doubt exists about the Company’s ability to continue as a going concern, as evaluated based on applicable guidelines. We are actively exploring additional required funding through non-dilutive grants and contracts, partnering, debt or equity financing pursuant to our plan. We believe that the Company has on-going access to the capital markets including the “At-The-Market” (ATM) agreement that became active around April 5, 2024. We have previously adjusted our objectives and development plans on the basis of available resources and we will continue to do so.

This year, we have re-calibrated our priorities to seek opportunities with early fruition and lower cost compared to going after the longer horizon opportunities such as pediatric RSV treatment. We note that the Phase II clinical trial evaluating NV-387 for V-ARI/V-SARI will provide us with required information to move further into a Phase III for pediatric RSV approval.

We have several important milestones in the new year:

Completion and submission of the Phase I Clinical Study Report to the Indian regulatory Agency.

Filing of the Phase II Clinical Trial Application for the evaluation of NV-387 as a treatment for MPox to ACOREP in DRC, its Approval by the regulator, Commissioning of the clinical trial, and Interim Results.

Filing of Orphan Drug Designation applications to the US FDA as cited above, and their anticipated approval.

Filing of a pre-IND with the US FDA towards NV-387 for Smallpox treatment under the “Animal Rule”.

Filing of an IND with the US FDA towards evaluation of NV-387 as a Smallpox treatment leading to registration.

Filing of the Phase II Clinical Trial Application for the evaluation of NV-387 as a treatment for Viral Respiratory Infections in India, its Approval by the regulator, and Commissioning of the clinical trial, and Interim Results.

As we meet the milestones, we believe we will be able to raise financing for further regulatory activities for NV-387 registration via non-dilutive grant funding, partnership revenues, as well as equity-based funding.

We believe the Company has a bright future. Our Phase II clinical stage drug NV-387 has completed Phase I clinical trial with the successful results that there were no drop-outs, and there were no reported adverse events, both of which clearly indicate excellent safety and tolerability in humans. NV-387, as mentioned above, is likely to become a revolutionary broad-spectrum antiviral therapeutic, that could change how we treat viral infections forever. In addition, the Company has developed a pan-Herpesvirus drug, NV-HHV-1. Its skin cream formulation for the treatment of Shingles rash, Chickenpox, HSV-1 Cold Sores, and HSV-2 Genital Ulcers, has completed certain IND-enabling non-clinical studies. NV-HHV-1 has demonstrated effectiveness in a human skin model of VZV infection (Varicella-Zoster-Virus, which causes Chickenpox and Shingles). A systemic form of the herpesvirus drug is in development. The Company has also developed an anti-HIV drug, NV-HHV-1, which the HIV viruses would not be able to escape despite rapid virus evolution. NV-HHV-1 has demonstrated strong effectiveness superior to triple-drug combination HAART therapy in a humanized animal model of HIV infection.

The Company’s technology is based on mimicking the host-side binding sites that the virus uses which remain the same despite several and extensive changes in the virus. We design and make chemical mimics of these sites to create virus-binding ligands that we attach to a base polymer. This makes the drug look like a cell membrane to the virus. The nanoviricide drug is thus designed to fool the virus into entering the nanoviricide drug micelle and uncoating itself by using the virus’s own smarts against it.

We believe viruses would not be able to escape nanoviricide drugs because of this design. In contrast, viruses readily escape vaccines, antibodies, and most of the small chemical drugs.

Oral NV-387 was found to be superior to the three known drugs oseltamivir (Tamiflu®, Roche), peramivir (injection, Rapivab®, BioCryst), as well as baloxavir (Xofluza®, Shionogi/Roche) in a lethal lung infection animal model of Influenza.

Oral NV-387 was found to cure lethal lung RSV infection in an animal model. There is no current approved drug for treating RSV infection.

Previously, NV-387 given both orally and as I.V. injections was found to be substantially superior to remdesivir (injection, Gilead) in a lethal lung infection animal model for COVID-19.

Oral NV-387 was found to be equivalent to or superior than tecovirimat (TPOXX®, SIGA) in two different lethal animal models of orthopoxvirus diseases. One of these models simulated skin infection which is the primary route of MPox Clade II infections. Another animal model simulated direct lung infection which is the likely route of Smallpox infection in case of bioterrorism.

About NanoViricides

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

View the original press release on ACCESS Newswire

Unlimited use certificate lifecycle management and private PKI disrupt an overpriced, restrictive market by offering one simple subscription fee

SAN DIEGO, CA / ACCESS Newswire / October 2, 2025 / Garantir, a leader in enterprise cryptographic security, today announced the launch of its Unlimited Certificate Lifecycle Management (CLM) and Private Public Key Infrastructure (PKI) offering, designed to eliminate costly certificate outages, simplify compliance, and reduce enterprise PKI costs by up to six figures annually.

For decades, cryptography has been the backbone of digital trust. Yet managing the certificates that secure websites, applications, devices, and identities has only grown more complex. Certificates and keys are getting larger, renewals are becoming more frequent, and with new compliance changes set to take effect in March 2026, organizations will soon face a heavier operational burden than ever before. Despite these pressures, incumbent vendors continue to rely on outdated, per-certificate pricing models with confusing tiers and hidden add-ons that make enterprises feel held hostage by unpredictable, skyrocketing bills.

Breaking the Enterprise Pricing Barrier

Garantir’s new model replaces per-certificate pricing with a simple, predictable subscription:

Unlimited CLM: $99K/year

Private PKI: $25K/year

Unlimited includes no cap on certificates or certificate types under management, full discovery, automated renewals, support for public third-party trusted and private CAs, policy enforcement, connectors, users, and teams – with no hidden fees, no tiers, and no per-certificate counting.

By removing artificial price barriers, certificates can be monitored and renewed on time, eliminating the risk of outages, audit failures, and service disruptions.

With new short-lived certificate requirements on the horizon, enterprises face an unprecedented operational burden to keep pace with accelerated renewals. Affordable, enterprise-scale CLM automation is no longer optional, it’s essential to maintain trust and uptime.

“Short-lived certificate rules will drastically increase the renewal volume and complexity organizations must manage,” said Trell Rohovit, Garantir CEO. “Traditional CLM hasn’t evolved in line with technology. Automation and integration should have driven prices down years ago, but enterprises are still being charged like it’s 2015. If companies can’t automate at scale, they’re exposed to outages, compliance failures, and unnecessary risk. We are aligning price-to-value to ensure automation is accessible and affordable so every enterprise can meet this challenge head-on.”

Driving Security and Savings

Over the past decade, some of the world’s largest and most trusted digital platforms have been unexpectedly taken offline due to expired or misconfigured digital certificates. Analysts have repeatedly noted that these incidents are not isolated mistakes, but systemic risks that highlight how fragile critical systems become when certificate lifecycle management is left to manual tracking or fragmented processes.

By shifting to Garantir’s simple-fee model, enterprises can redirect up to six-figure savings to other important security initiatives such as post-quantum cryptography readiness, ransomware defense, code signing, privileged access management, secrets management, etc., accelerating progress toward broader security goals.

True Unlimited, Seamless Integration, Rapid Deployment

Unlimited with Garantir truly means unlimited. Certificates across the enterprise can be discovered, enrolled, renewed, and governed without counting, tiers, or hidden limits. This includes full support for standard enrollment protocols such as SCEP, EST, and ACME, native orchestration with enterprise applications and platforms, and integrations with leading trusted public CAs including, but not limited to, DigiCert, Sectigo, and GlobalSign, as well as private PKIs like Microsoft, AWS Private CA, Garantir CA, and EJBCA.

In addition, Garantir enables CLM for TLS with properly protected keys in HSMs as well as just-in-time provisioning.

With enterprise-scale capacity built in, organizations can consolidate certificate lifecycle management across diverse environments, ensure certificates are continuously monitored and renewed, and eliminate the risks of outages or audit failures.

Customers typically go live in days to weeks – not months – without re-engineering or costly consulting engagements.

By combining discovery, broad connector coverage, seamless app integration, HSM-protected keys, and just-in-time provisioning into a single predictable subscription fee, Garantir redefines what CLM + PKI should deliver for modern enterprises.

About Garantir
Garantir is a cybersecurity company that provides advanced cryptographic solutions to the enterprise. The Garantir team has worked on the security needs of businesses of all sizes, from startups to Fortune 500 companies. At the core of Garantir’s philosophy is the belief that securing business infrastructure and data should not hinder performance or interrupt day-to-day operations. With GaraTrust, Garantir’s flagship cryptographic services platform, private keys remain secured at all times, while a client-side hashing architecture ensures high performance for all cryptographic operations, including code signing, SSH, S/MIME, document signing, application-level data encryption, TLS, secure backup, and more. Explore https://www.garantir.io to learn more.

Contact Information

SOURCE: Garantir Cybersecurity

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / October 2, 2025 / The plastics market isn’t small change. It’s a $824 billion global arena – and it’s been hungry for proof. Not about the material itself, but about sustainability and recycling measures that can keep its environmental impact in check. The world is done with promises and pledges. What it demands now is verifiable evidence that recycled content is exactly what companies claim it to be.

That shift in expectation has exposed the weakness of decades of regulatory patchwork, greenwashing headlines, and conference speeches that never moved the needle. The market has boiled it down to a single truth: proof is currency. And in a $50 billion recycling market, that currency is worth a serious paycheck – one SMX (NASDAQ:SMX) is positioning itself to collect.

SMX doesn’t trade in abstractions and “hope-for’s”. Its molecular marker technology embeds proof at the material level, creating digital passports for plastics that survive the entire recycling loop. From collection through processing and back into new products, SMX tags materials with an unalterable identity – a marker that regulators, brands, and consumers alike can verify. That’s particularly important, given that mistrust has kept capital on the sidelines and slowed adoption in this sector. In that sense, SMX’s breakthrough isn’t just a scientific achievement. It’s economics.

Markets Demand “Proof” Over Promises

For the recycling market, the timing could not be more on queue. Global demand for recycled plastics is surging as governments impose quotas, consumer brands set targets, and investors push ESG funds to deliver measurable outcomes. Yet recycling rates remain stubbornly low, hovering in the teens in the U.S. and only modestly higher across Europe and Asia. The missing link has been verification. Without it, recycled plastics carry a discount, trust collapses, and the supply chain stalls. SMX’s technology flips that script – making recycled plastic a premium product with traceable value.

The better news is that SMX has already proven its technology at scale, first by marking and tracing 21 tons of natural rubber from tree to tire, and it is now replicating that same methodology across plastics globally. In ASEAN, SMX has locked in multiple deals (with Bio-Packaging, Skypac, A*STAR, among others) to embed molecular markers at the point of extrusion, turning every film, wrapper or bag into a blockchain-verifiable digital twin.

In the U.S., SMX recently forged a strategic partnership with Tradepro to deploy FDA-compliant molecular marking in food-grade plastics, bringing traceability into one of the most heavily regulated segments. And, in collaboration with REDWAVE, SMX has completed proof-of-concept trials demonstrating the sorting and verification of flame-retardant and black plastics in recycling streams.

Proof Points Matter

With every new proof point across geographies and material types, the company isn’t just participating in the circular economy; it’s becoming its operating system. And in markets this large, the operating system tends to capture the lion’s share of the value.

The story here is not regulation. Regulation sets the stage. The story is monetization, transforming waste into verifiable assets. SMX’s molecular markers, combined with blockchain and tokenized credits like the Plastic Cycle Token (PCT), give plastics a tradable identity that can be bought, sold, and valued. That’s more than compliance. That’s an entirely new asset class built from materials the world once paid to discard.

The $50 billion question is no longer whether recycled plastics will matter. It’s who will control the proof layer that makes the system run. SMX has spent years building the answer, and now it’s entering the market at the exact moment proof has become non-negotiable.

For brands, regulators, and stakeholders, that’s not just a shift. That’s an entry point worth seizing. And all it takes is a phone call to start doing just that.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters)

View the original press release on ACCESS Newswire

More than 25,000 people from around the world gathered in St. Augustine, FL, to celebrate music and nature

SAINT AUGUSTINE, FL / ACCESS Newswire / October 2, 2025 / Live Wildly and Sing Out Loud Festival, with the help of more than 25,000 music fans, raised over $130,000 for conservation in St. Johns County, FL. The funds will go directly toward local land conservation initiatives that safeguard Florida’s wild beauty.

The funding was raised through a portion of ticket sales from Sing Out Loud Festival’s Live Wildly Showcase, a mission-driven music festival designed to spark deeper connections to Florida’s wild places. Held Sept. 20-21 in historic St. Augustine, FL, the festival weekend featured 14 headliners such as platinum-selling artist Hozier, indie star Beabadoobee and folk-pop artist Vance Joy.

“Nature, like music, has the power to move people,” said Lisa Shipley, CEO of Live Wildly. “We’re proud to partner with Sing Out Loud to inspire people to protect Florida’s wild lands. People protect what they love. From the food we eat to the air we breathe to the places we recreate, nature plays a vital role in our daily lives.”

In between world-class acts, festival attendees explored the Live Wildly tent, where they were surrounded by the sights of Florida’s unique natural areas. Inside the air-conditioned, springs-themed environment, guests cooled off while learning about Florida’s iconic freshwater springs and the many species that depend on them. Vibrant imagery and educational displays throughout the venue highlighted the importance of protecting Florida’s fragile ecosystems. Near the center of the event, Live Wildly showcased the return of its 15-foot inflatable Florida panther and debuted a new cub, a nod to the critically endangered species with only a little over 200 believed to remain in the wild.

This marks the second consecutive year Live Wildly has teamed up with Sing Out Loud to raise funds for Florida conservation. Year-round, Live Wildly collaborates with public and private partners across the state to connect people with Florida’s wild places and inspire lasting support for protecting them.

“Our partnership with Live Wildly reflects what Sing Out Loud Festival is all about – using the power of music to bring awareness and inspire action,” said Gabe Pellicer, CEO & President of SJC Cultural Events, Inc., the 501c3 organization that produces Sing Out Loud Festival. “Thanks to this collaboration, we’ve shown that when music and conservation come together, we can make a real impact for Florida’s wild places. And that impact goes beyond one weekend of music – it helps safeguard the lands and waters that define Florida’s identity and sustain our communities for generations.”

Live Wildly’s mission is the long-term protection of Florida’s lands and waters, starting with a permanently connected Florida Wildlife Corridor. The Corridor, established in 2021, is an 18-million-acre network of lands and waters stretching from the Everglades to the Panhandle. It not only provides habitat for almost 2,000 different species – including the iconic Florida panther, manatees, and the Gopher tortoise, but also supports more than 100,000 jobs and generates $30 billion in annual revenue through recreation, tourism, agriculture and other industries.

SOURCE: Live Wildly Foundation

Related Images

View the original press release on ACCESS Newswire

With more than four million merchants worldwide and operations across 35+ markets, SumUp doubles down in the U.S. with a full ecosystem of solutions – from point-of-sale and loyalty to invoicing

BOULDER, CO / ACCESS Newswire / October 2, 2025 / SumUp, the global financial technology company serving more than four million small businesses worldwide, today announced a renewed commitment and investment in the U.S. market. Building on its established U.S. presence, the company is bringing greater recognition to the entrepreneurs and small business owners it serves with a comprehensive suite of tools designed to help companies get paid, run operations, and grow. This U.S. push comes at an inflection point after proving its model globally and reaching a massive scale.

The company operates in more than 35 markets and processes over one billion transactions annually, scaling from tens of millions just a few years ago. Unlike many U.S.-focused providers, SumUp combines this global reach with a broad ecosystem, from point-of-sale systems to loyalty and kiosks, making it one of the few SMB payment companies able to deliver enterprise-level sophistication to small businesses.

“Small businesses drive the economy, but too many are still locked out by costly and fragmented systems — we’re here to change that with a point-of-sale solution for small businesses designed specifically with their business and customer retention and acquisition needs in mind,” said Andrew Helms, CEO – USA at SumUp. “Over the last decade, we’ve proven that you don’t need to be a large enterprise to access world-class financial tools. With substantial investment and strategic acquisitions, such as Fivestars, we have built a solution to empower U.S. merchants to grow their businesses with ease.”

SumUp is already embedded in the fabric of American entrepreneurship, supporting thousands of small businesses – from pet stores, cafés, and bubble tea shops to liquor, vape, and tobacco shops. These existing relationships provide a strong foundation for SumUp’s deeper U.S. investment and continued growth.

As part of its expanded U.S. strategy, SumUp is focused on:

• SumUp POS, fueled by an industry-leading loyalty and customer communication platform.

• Supporting products and features that help merchants run and grow their businesses effortlessly, such as Kiosk, invoicing, inventory management, and banking solutions.

• Top-notch customer support, effortless onboarding, and a seamless and consistent experience.

SumUp is committed to becoming the leading financial services partner for small businesses across the U.S. by enhancing their access to and experience as it expands its operations.

About SumUp

SumUp is a global financial technology company driven by the mission of empowering small businesses all over the world. Established in 2012, SumUp is the financial partner for more than 4 million entrepreneurs in over 35 markets worldwide. In the United States, SumUp offers an ecosystem of affordable, easy-to-use financial products, such as point-of-sale and loyalty solutions, kiosks, card readers, and invoicing.

For more information, please visit https://www.sumup.com

Contact Information

Kite Hill PR
sumup@kitehillpr.com

SOURCE: SumUp

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / October 2, 2025 / The market doesn’t reward talk. It rewards proof. Nowhere is that more obvious than in the debate over supply chain circularity. Recycling pledges and sustainability headlines have been plentiful, but hard evidence of what’s really moving through the system has been scarce. That’s where SMX (NASDAQ:SMX) comes in. It provides the proof that has long been missing, embedding molecular markers directly into materials and positioning itself as the ultimate facilitator of material efficiency.

And that’s the real shift-SMX doesn’t just support sustainability, it hardwires it. Its technology transforms good intentions into a functioning system. By creating a living ledger of how resources are used, reused, and monetized, it moves the conversation from pledges to proof. This isn’t a badge of honor manufacturers can pin to an ESG report-it’s a framework that makes products, and the promises behind them, measurable and enforceable. Proof no longer lives in paperwork. It lives in the product itself.

This isn’t theory. SMX has already shown the model works across global industries. In Latin America, it traced natural rubber from the tree to the tire, setting a precedent for transparency in one of the world’s most complex supply chains. In Europe, it has marked metals, proving that high-value resources can be audited with precision. In Asia, it brought material efficiency to textiles, giving global brands a way to turn sustainability claims into hard data. These aren’t pilots. They are building blocks of a new system where proof is the currency of circular economies.

Now comes the U.S. chapter. By teaming with Tradepro, a leader in plastics recycling and distribution, SMX is pushing material efficiency straight into the American market. The entry point is food-grade plastics-one of the toughest, most regulated categories. If SMX’s earlier projects proved the model globally, this deal proves that material efficiency can now anchor itself in the largest consumer market on the planet.

From Tradepro’s History to a Shared Future

Tradepro’s history is a story of scale. With decades in plastics sourcing, recycling, and distribution, the company has kept manufacturers supplied and costs in check while navigating the volatility of global markets. That track record makes it the perfect U.S. partner for SMX. Material efficiency has always been about more than recycling-it’s about lowering costs, strengthening supply chains, and making better use of scarce resources. Tradepro knows those pressures firsthand.

For Tradepro, the partnership unlocks a new opportunity: the ability to offer proof as part of its value chain. SMX’s markers survive every stage of production-resin, compounding, molding, packaging-and can be verified without damaging the product. That means every shipment of recycled material is no longer just material. It’s certified efficient, auditable, and defensible.

For SMX, Tradepro delivers a ready-made network. Instead of entering the U.S. market cold, SMX is stepping into established distribution lines that touch industries across the country. That’s how material efficiency moves from concept to standard: by embedding itself into the companies that already keep supply chains running.

Proof as Currency in Food-Grade Plastics

Food-grade plastics are where the stakes are highest. Regulators demand the strictest standards, consumers demand transparency, and brands face heavy penalties for falling short. Until now, recycled content in food packaging has been a numbers game based on trust-audits, certifications, and self-reported claims. In other words, a shaky system.

SMX’s FDA-compliant markers rewrite that equation. Every bottle, wrapper, and container can now carry its own invisible passport, verified on demand and tied to blockchain records. That turns material efficiency from an aspiration into an asset. Companies no longer have to guess or argue about compliance-they can scan and know.

The impact is enormous. Compliance becomes simpler, ESG claims become bulletproof, and recycled content takes on tangible value. In effect, material efficiency itself becomes tradable. This isn’t just about greener packaging. It’s about proving efficiency at the molecular level and turning that proof into economic leverage.

A First Step Into the U.S. Market

Global projects have already proven SMX’s reach. Rubber, metals, textiles-each has shown that material efficiency can be embedded across industries. But the U.S. market is its own test of scale. It’s where regulation, supply chain fragility, and investor attention collide. The Tradepro alliance marks SMX’s first major step into this arena, placing the company directly in one of the most pressing sectors.

The timing couldn’t be sharper. States like California are enforcing strict recycled content laws, federal regulators are circling with broader mandates, and companies face real costs for missing the mark. Material efficiency isn’t a nice-to-have in this environment. It’s survival. And SMX offers the one thing that cuts through the noise: auditable proof.

There’s also the economic side. By proving recycled content locally, SMX and Tradepro reduce reliance on imported feedstock, lower transportation costs, and strengthen domestic supply chains. That’s material efficiency at its most practical-doing more with what’s already here and cutting the hidden costs out of the loop.

Building the Arsenal

Step back, and the bigger strategy is clear. SMX isn’t collecting projects-it’s building an arsenal of proof points that turn material efficiency into global infrastructure. Natural rubber, textiles in Europe, metals with memory, and now plastics in the U.S. Every partnership is another branch growing from the same trunk: embedding proof at the molecular level and scaling it across the economy.

That arsenal matters because sustainability doesn’t move on good intentions. It moves on systems that make efficiency measurable and enforceable. SMX’s technology, backed by block-chain records and digital assets, is that system. It transforms waste into certified value and redefines efficiency as a financial standard, not just an environmental goal.

And that’s the story that should grab every stakeholder’s attention. This mission isn’t about plastics in isolation or rubber or textiles alone. It’s about SMX creating the architecture of a new economy where material efficiency isn’t just tracked-it’s traded. Proof has become the new currency, and SMX isn’t just minting it. It’s building the marketplace.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / October 2, 2025 / We are closer than we think. Not closer in the foggy, geopolitical sense. Closer in the literal tick-tick of a clock. A recent bust in New York City uncovered hundreds of servers and more than 100,000 SIM cards, all ready to flood networks and overwhelm emergency channels. That plot was low-tech, cheap, and terrifyingly effective. It did not need explosives. It only needed numbers. Numbers that turn into noise, noise into chaos, and chaos that very quickly becomes a national emergency.

Imagine fifty cities all trying to call 911 at once, only to hear dead air. Imagine air traffic control losing telemetry because sensors began reporting fiction. Imagine hospitals having to triage not patients but systems. That is not a Hollywood script. It is a plausible chain of failures that begins with cloned SIMs being activated en masse. When authenticity is assumed but not verified, the infrastructure that underpins daily life becomes brittle. The margin for error is not small. It is zero.

Here is the blunt truth. Attackers want asymmetry. They spend pennies to buy leverage that costs nations millions to counter. Flood a telecom network with phony traffic and you do more than interrupt service. You force a reaction. Regulators clamp down. Companies reroute dollars into crisis control. Governments mobilize. A tiny operation becomes an international incident. That is the leverage of Zero Day. And just like in the series, it is cheap to start and expensive to stop. But SMX (NASDAQ:SMX) has the technology to clip the wires and stop that clock’s countdown.

When the Bell Rings, Response Is Not Measured

And, it better. The danger is not the initial interruption. The danger is the escalation that follows. A communications collapse will not be met with calm, careful inquiry. It will be met with urgency, suspicion, and action. Treating such an event as an act of war becomes a live possibility because the attack bypasses traditional markers of conflict. No flag flies overhead. No carrier arrives. Yet the impact is strategic.

Countermeasures will ripple outward, alliances will be tested, and military might won’t be tested; it will be proven. Markets will reassess what they thought was secure. Supply chains will be audited in panic. The economy will not wait for reports or commissions to be issued. It will pause. And when the pause hits, the cost accrues in real time. Minutes are not an abstract unit. Minutes are billions of dollars in frozen trades, stalled logistics, and failed medical procedures.

That is the scale of the risk. The world is not safe because threats are dramatic. The world is vulnerable because threats are mundane and plausible. A SIM-farm in a basement can do more damage, faster, than a thousand headlines.

Proof at the Material Level Stops the Countdown

This is where SMX matters most. Not because it promises miracles. Because it changes the rules. SMX embeds microscopic, immutable markers into the physical fabric of devices and components. These markers are paired with digital ledgers that instantly verify identity. A SIM that does not match its recorded identity cannot be trusted to join a live network. A router that fails its scan does not get installed into a critical path. A sensor out of custody does not feed control systems.

Verification shifts from a forensic afterthought to an operational gatekeeper. A single scan answers three deadly questions: is this real, where did it come from, and has it been tampered with. That speed is the difference between prevention and catastrophe. In a world measured in ticks, seconds are everything.

This system does not require armies of inspectors. It requires the right architecture. Put proof in the material, and the problem shifts from chasing attackers to denying them the tools that make attacks scale. Counterfeit economies thrive when anonymity is cheap. SMX makes anonymity expensive.

Prevention Beats Reaction Every Time

The SIM-farm bust should be a wake-up call. It should be the signal to move from playbook to practice. Investing in systems that verify hardware at the point of origin and the point of activation is not optional. It is the only sane course in a world where low-cost hacks can trigger geopolitical fireworks.

When components carry identity, the first domino never tips. When every device can be scanned and verified in seconds, the attacker’s time advantage evaporates. Prevention becomes both a national security posture and a market differentiator. Companies that can certify the provenance of their hardware gain resilience. Investors who recognize platforms that harden supply chains get optionality.

We used to think apocalypse had a big signature: a missile, a storm, an obvious enemy. The next one will come wearing everyday clothes. It will rely on scale and plausibility, not spectacle. That is what makes it dangerous and what makes proof essential. SMX is not selling fear. It is selling the mechanism that keeps the clock from ever reaching zero.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire